<DOC>
	<DOCNO>NCT00663832</DOCNO>
	<brief_summary>This Phase Ib dose escalation study design characterize safety , tolerability preliminary efficacy i.v . panobinostat ( LBH589 ) combination docetaxel prednisone 1st line treatment patient hormone refractory prostate cancer .</brief_summary>
	<brief_title>A Dose Finding Study With I.V . Panobinostat ( LBH589 ) , Docetaxel , Prednisone Patients With Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Inclusion criterion : HRPC patient Evidence disease progression Self care , able perform light work activity Willing use contraception throughout study 12 week study completion Exclusion criterion : History cancer curatively treat evidence disease 5 year . Prior radiotherapy within 3 week start study treatment Prior radiopharmaceutical ( strontium , samarium ) . Impaired cardiac function Heart disease Liver renal disease impaired function . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Male</keyword>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>HRPC</keyword>
	<keyword>DACi</keyword>
</DOC>